Amgen/UCB Poised For Osteoporosis Drug Filing On Back Of Mixed PhIII
This article was originally published in Scrip
Amgen Inc. and partner UCB will file their osteoporosis drug romosozumab this year on the back of mostly positive Phase III data in postmenopausal women – but where will the drug be positioned against Amgen's own Prolia (denosumab) and other available treatments?
You may also be interested in...
As Amgen’s main hope for extending its bone health franchise, romosozumab faces a second review at the FDA with a fuller dataset and an external analysis of cardiovascular risk.
The US FDA has surprised no-one with a Complete Response Letter for Amgen and UCB's novel osteoporosis treatment Evenity but, with luck, analysts say the product might still reach the market in 2018-19 and garner sales over £500m.
Amgen Inc. and partner UCB Group have filed their osteoporosis drug romosozumab, which is anticipated to drive sales of more than $700m worldwide by 2023, in the US for the treatment of postmenopausal women at risk of fractures.